Final answer:
The company's decision to sell an unapproved drug in another country is an issue within the ethical domain, balancing legal permissibility and ethical responsibility.
Step-by-step explanation:
The decision of a company to sell a new drug in another country before receiving FDA approval in the United States falls into the ethical domain. While it is legal to sell the drug where it may not require such stringent approval processes, the ethical considerations come into play regarding the safety and efficacy of the drug for consumers in the other country. The ethical domain is concerned with what is right and wrong, apart from what is specifically lawful or within one's rights.